Higher mortality rate in Lung Cancer patients during COVID-19 pandemic

Dayyaneh feyzbakhsh, Ali Nemati Siyahmazgi, Hossein Javid ©

Higher mortality rate in Lung Cancer patients during COVID-19 pandemic

کد: G-82679

نویسندگان: Dayyaneh feyzbakhsh, Ali Nemati Siyahmazgi, Hossein Javid ©

زمان بندی: زمان بندی نشده!

برچسب: بیوشیمی

دانلود: دانلود پوستر

خلاصه مقاله:

Background and Aim

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by the severe acute respiratory syndrome (SARS-CoV-2). Lung cancer is the most common cancer among males with high mortality rate. lung cancer Patients may have severe COVID-19 complications. Optimal cancer care during COVID-19 pandemic could be designed if patient-specific and cancer-specific features which affect the severity of COVID 19 are better understood.

Methods

Blank

Results

Reportedly, cancer patients have a higher risk of infection with SARS-CoV-2 (0.79%), in comparison with non-cancer patients (0.37%) because of their suppressed immune state caused by the malignancy and anticancer treatments. COVID-19 in lung cancer patients (7 out of 12) and patients aged 60 years or older was highly severe (62% hospitalized, 25% mortality). However, this severity only caused a small fraction of lung cancer deaths during pandemic (approximately 11%). COVID-19 severity factors to a large extent are related to patient-specific features such as smoking and chronic obstructive pulmonary disease. On the other hand, Cancer-specific features like prior thoracic surgery/radiation and systemic therapies did effect severity. Antigen supertypes of Human leukocyte were normally similar in mild or severe COVID-19 cases compared with non-COVID-19 controls. inflammatory monocyte and macrophage activation cause acute lung injury that results in release of proinflammatory cytokines such as interleukin (IL)-6, IL-1 and tumor necrosis factor-α which have vital role in immune-associated pneumonitis. Thus, these cytokines may be a therapeutic target when T cell is dominant in infiltration or there are signs of increased IL-6 inflammation as in increased C-reactive protein.

Conclusion

The mortality rate in lung cancer patients are higher than normal population. The high severity in lung cancer patients is linked with COVID-19 and features that are patient specific are the most determining factors of severity. A fairly good treatment option could be hydroxychloroquine combined with azithromycin. Of note, it is better to reduce hospital visits as they could increase the risk of nosocomial transmission

Keywords

Lung Cancer; COVID-19; SARS-CoV-2

دیدگاه ها (0)

تاکنون دیدگاهی منتشر نشده است. شما اولین نفر باشید!

ارسال یک دیدگاه

ارسال دیدگاه توسط مدیریت بسته شده است.